EN DE

Camlin Fine Sciences Limited (CAMLINFINE) Fair Value & Analysis

Basic Materials · IN · Market cap ₹26.1B

CF Camlin Fine Sciences Limited CAMLINFINE · NSE
Price₹107.94
Fair Value₹27.43
Upside-74.6%
Quality31/100
Watch Camlin Fine Sciences Limited for free, get notified when fair value or trend changes. Watch for free
Expensive Growth
Thin margins · 1.6% net margin
Low debt · negative free cash flow
Trails peers (2/10)
Narrow moat 20/100
Evidence: High Range ₹19.20 – ₹30.56 Share as image

Fair value as of: Aug 2, 2026

From 17 valuation models · updated 11 days ago

Share price −14.4% over the past month.

Below-average quality, and screening another 75% overvalued on our models.

What matters now

  • The price sits above even our optimistic bull case (₹30.56). The favourable scenario is already priced in.
  • Weak quality (31/100) and above fair value at the same time, the margin of safety is missing on both counts.
Share this valuation: 𝕏 WhatsApp

Price vs Fair Value (5 years)

₹327.53 ₹86.95 Fair Value ₹27.43 Apr 2021 Aug 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 2, 2026.

How to read this chart

60‑month range ₹86.95 – ₹327.53 · fair‑value band ₹19.20 – ₹30.56 · the ₹107.94 price screens above the ₹27.43 fair value. Dashed = 300-day average. As of Aug 2, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

Camlin Fine Sciences Limited (CAMLINFINE) currently trades at ₹107.94, while our model-based Fair Value estimate is ₹27.43, implying the stock looks roughly 74.6% overvalued today. The Quality Score stands at 31/100 (below-average quality), in the Basic Materials sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).

Over the trailing twelve months, Camlin Fine Sciences Limited generated revenue of ₹17.2B at a net margin of 1.6%. Revenue declined 2.9% year over year. It earns a return on equity of -3.4%. Net debt stands at ₹5.7B. Fundamentals as of Aug 2, 2026

Our scenario range runs from ₹19.20 (bear case) to ₹30.56 (bull case); at ₹107.94, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 67% below its 52-week high and 12% above its 52-week low, currently below its 200-day average. For context, the median of 10 Basic Materials peers we cover trades at -58% fair-value upside, at -75%, CAMLINFINE screens richer than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Note: the current price implies far more future growth than the conservative anchors of our models allow (base growth is deliberately capped, we do not regard such extreme rates as sustainable). Our models are not designed for expectations this high; that is why the individual models scatter extremely (₹4.98 to ₹52.29). Read the values as a conservative anchor, not as a price target.
Model Bear Bear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull Bull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence
Highest evidence
Residual Income ₹39.21 ₹38.36 ₹32.18 76
ROIC Compounder ₹3.16 ₹4.98 ₹6.57 72
Gordon GGM ₹13.45 ₹27.96 ₹44.35 70
All 17 models by family
DCF Models
Owner Earnings ₹21.41 ₹48.88 ₹99.56 31
Earnings-Based
Graham-Dodd ₹9.78 ₹52.29 ₹72.43 54
Lynch FV ₹14.44 ₹20.62 ₹26.81 50
PEG = 1.0 ₹14.44 ₹20.62 ₹26.81 46
EPV ₹3.16 ₹4.98 ₹6.57 59
Dividend Discount
Gordon GGM ₹13.45 ₹27.96 ₹44.35 70
DDM Multi-Stage ₹13.45 ₹23.57 ₹29.34 61
Multiples
P/E Multiple ₹18.34 ₹24.45 ₹30.56 63
P/S Multiple ₹18.34 ₹24.45 ₹30.56 58
P/B Multiple ₹18.34 ₹24.45 ₹30.56 55
EV/EBIT ₹5.62 ₹10.08 ₹14.54 53
EV/EBITDA ₹29.48 ₹41.90 ₹54.32 54
EV/Revenue ₹3.83 ₹8.80 ₹13.78 43
Asset-Based
NCAV (Graham) ₹27.09 ₹36.31 ₹54.19 50
Economic Profit
Residual Income ₹39.21 ₹38.36 ₹32.18 76
ROIC Compounder ₹3.16 ₹4.98 ₹6.57 72
Growth Earnings
Growth-Adj P/E ₹19.20 ₹27.43 ₹35.66 68

Widest divergence: DCF Models (₹48.88) versus Economic Profit (₹4.98). Highest evidence: Residual Income (76).

Notify me when CAMLINFINE reaches fair value

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.

Key figures & financial health

Revenue (TTM) ₹17.2B
Revenue growth (YoY) -2.9%
Net margin 1.6%
Return on equity -3.4%
Free cash flow −₹331M FY2026
Operating margin 0.1%
More key figures
EPS (TTM) ₹-1.60
EPS growth (YoY) +154%
Net debt ₹5.7B FY2026

Figures from reported company fundamentals · as of Aug 2, 2026. TTM = trailing twelve months.

Quality Score breakdown

Overall quality 31/100

Of which business quality 33 · Market factors (momentum, volatility) 19

Profitability 31
Margins and returns on capital today
Quality Growth 27
Are margins and returns improving?
Cashflow 14
Earnings quality: real cash, not paper profit
Fin. Strength 42
Balance sheet, leverage, solvency risk
Investment 77
Disciplined investing over empire-building
Low Volatility 47
Calm price path (market factor)
Momentum 11
Price trend over the last 3–12 months (market factor)
52W Momentum 3
Distance to the 52-week high (market factor)
Net Issuance 20
Buybacks instead of dilution

Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.

About the company

Camlin Fine Sciences Limited, together with its subsidiaries, research, develops, manufactures, and markets specialty chemicals, ingredients, and additive blend products in India and internationally.

Full company description

Camlin Fine Sciences Limited, together with its subsidiaries, research, develops, manufactures, and markets specialty chemicals, ingredients, and additive blend products in India and internationally. The company offers shelf-life solutions, which include basic ingredients, such as tert-butylhydroquinone (TBHQ), Butylated Hydroxyanisole (BHA), Butylated Hydroxytoluene (BHT), and Ascorbyl Palmitate (ASP); aroma ingredients, including vanillin and ethyl vanillin, natural vanillin, and some of its combinations; performance chemicals that include Hydroquinone (HQ), Catechol (CAT), Monomethyl Ether of HQ (MEHQ), tert butylcatechol (TBC), Guaiacol, and Veratrole; and health and wellness products comprising algae based products, such as Omega 3 fatty acids. It sells its prodycrts under the Xtendra, Nasure, Ezential, adorr, Dinamic, and Biosus brands. The company's products are used in food and beverage, pet food and rendering, animal nutrition, petrochemical, nutrition and health, biofuel, agrochemical, pharmaceutical, polymers, fragrance and flavor, and dyes and pigments industries. The company was formerly known as Camlin Fine Chemicals Ltd. and changed its name to Camlin Fine Sciences Limited in August 2011. Camlin Fine Sciences Limited was founded in 1931 and is headquartered in Mumbai, India.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2022 – FY2026 · reported fiscal years

Camlin Fine Sciences Limited reported revenue of ₹17.2B in FY2026 versus ₹14.0B in FY2022, a compound +5.2%/yr. Reported net income was ₹276M in FY2026, compounding −17.9%/yr from FY2022.

Growth Quality 44/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Latest Revenue (FY 2026)
₹17.2B
Latest YoY
+3.4%
Avg. growth/yr (3Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+0.8%
Avg. growth/yr (5Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+7.9%
Avg. growth/yr (19Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+20.9%
Revenue +5.2%/yr
FY22 ₹14.0B
FY23 ₹16.8B
FY24 ₹16.0B
FY25 ₹16.7B
FY26 ₹17.2B
Net income −17.9%/yr
FY22 ₹607M
FY23 ₹521M
FY24 −₹928M
FY25 −₹1.4B
FY26 ₹276M

CAMLINFINE screens 75% overvalued. Compare with Linde plc →

Share or link this analysis
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Cite: Fair Value Calculator (2026). "Camlin Fine Sciences Limited Fair Value". https://www.fairvalue-calculator.com/stock/CAMLINFINE

Peer Group

Specialty Chemicals · 674 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Quality Score 31 · Bottom 25%
Fair Value upside −75% · Bottom 25%
Return on assets 1% · Below median
Net margin (TTM) 2% · Below median
Operating margin (TTM) 0% · Bottom 25%
Revenue growth -3% · Below median
Debt / equity 0.29× · Higher than median

Valuation Multiples vs Specialty Chemicals median · lower = cheaper

P/S (TTM) 0.02× · Cheaper than 75% of peers
EV/EBITDA 1.6× · Cheaper than 75% of peers

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

VALUE 0 · sector 0
FUTURE 0 · sector 19
PAST 0 · sector 23
HEALTH 85 · sector 95
DIVIDEND 0 · sector 25

VALUE 0: the price sits above our fair-value range.

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.

Similar stocks

10 more Specialty Chemicals stocks, each showing price versus our Fair Value estimate (as of Aug 2, 2026).

Stock Price Fair Value vs Fair Value
Linde plc LIN $489.98 $222.03 -55%
Nan Ya Plastics Corporation 1303 181.50 TWD 255.83 TWD +41%
Wanhua Chemical Group 600309 ¥70.04 ¥68.03 -3%
Novozymes A/S NSISB kr 428.20 kr 179.66 -58%
Asian Paints Limited ASIANPAINT ₹2,689 ₹668.81 -75%
Solar Industries India Limited SOLARINDS ₹18,236 ₹2,793 -85%
Pidilite Industries Limited PIDILITIND ₹1,560 ₹351.84 -77%
PT Chandra Asri Pacific Tbk TPIA 1,805 IDR 2,888 IDR +60%
Linde India Limited LINDEINDIA ₹7,115 ₹757.93 -89%
Berger Paints India Limited BERGEPAINT ₹493.70 ₹164.29 -67%

Compare Camlin Fine Sciences Limited with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Explore undervalued stocks

More undervalued Basic Materials stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Frequently asked questions

Is Camlin Fine Sciences Limited (CAMLINFINE) overvalued or undervalued?
As of Aug 2, 2026, our model estimates a fair value of ₹27.43 versus a price of ₹107.94, about −75% (overvalued).
What is the fair value of CAMLINFINE?
Our model-based fair value for Camlin Fine Sciences Limited is ₹27.43 (as of Aug 2, 2026), built from audited fundamentals. The current price is ₹107.94.
What is the quality score of CAMLINFINE?
Camlin Fine Sciences Limited has a Quality Score of 31/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the revenue of Camlin Fine Sciences Limited (CAMLINFINE)?
Camlin Fine Sciences Limited reported trailing-twelve-month revenue of about ₹17.2B (latest available figure, as of Aug 2, 2026).
What is the net profit margin of CAMLINFINE?
The net profit margin of Camlin Fine Sciences Limited is about 1.6%, meaning it keeps roughly 1.6% of revenue as net income. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.

14 days Pro free · no card

Track Camlin Fine Sciences Limited and try Pro for 14 days

One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.

Zero risk: nothing is ever charged. After 14 days you decide whether to stay.